Evaluation in humans of a new, inactivated vaccine for Venezuelan equine encephalitis virus (C-84).
A new, formalin-inactivated vaccine for Venezuelan equine encephalitis (VEE) virus (C-84), prepared from an attenuated vaccine strain of virus (TC-83), was tested in humans. Only occasional, mild, local and systemic reactions were noted in 28 volunteers; no meaningful changes in clinical laboratory values occurred. The vaccine augmented preexisting titers of serum neutralizing antibody to VEE virus in seropositive recipients of TC-83 vaccine, and it induced high titers of neutralizing antibody in nonimmune subjects after one primary and two booster vaccinations. Circulating antibody persisted for at least 14 months in these persons. The neutralizing antibody produced after one dose of C-84 vaccine in immune subjects and after booster doses in nonimmune subjects had broad cross-reactivity within the VEE virus complex. The C-84 vaccine induced a VEE virus-specific lymphocyte transformation response. The vaccine was safe, and immunologic results showed it to be highly antigenic in healthy immune and nomimmune adults.
D000293:Adolescent; D000328:Adult; D000818:Animals; D000914:Antibodies, Viral / Q000096:biosynthesis*; D004663:Encephalitis Virus, Eastern Equine / Q000276:immunology; D004666:Encephalitis Virus, Venezuelan Equine / Q000276:immunology*; D004667:Encephalitis Virus, Western Equine / Q000276:immunology; D005260:Female; D006801:Humans; D007271:Injections, Intradermal; D007279:Injections, Subcutaneous; D008213:Lymphocyte Activation; D008297:Male; D008875:Middle Aged; D012882:Skin Tests; D014765:Viral Vaccines / Q000009:adverse effects / Q000627:therapeutic use*
D000914:Antibodies, Viral; D014765:Viral Vaccines